VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 487 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2014. The put-call ratio across all filers is 0.91 and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $364,000 | -2.9% | 22,838 | +5.5% | 0.02% | -20.8% |
Q2 2017 | $375,000 | +73.6% | 21,651 | +10.5% | 0.02% | +100.0% |
Q1 2017 | $216,000 | -58.0% | 19,600 | -44.7% | 0.01% | -61.3% |
Q4 2016 | $514,000 | -21.5% | 35,415 | +32.7% | 0.03% | -11.4% |
Q3 2016 | $655,000 | +26.2% | 26,697 | +3.6% | 0.04% | +20.7% |
Q2 2016 | $519,000 | -91.6% | 25,767 | -89.1% | 0.03% | -92.7% |
Q1 2016 | $6,197,000 | +259.0% | 235,623 | +1287.4% | 0.40% | +370.2% |
Q4 2015 | $1,726,000 | -85.6% | 16,983 | -74.7% | 0.08% | -85.7% |
Q3 2015 | $11,967,000 | +38.5% | 67,085 | +72.5% | 0.59% | +77.1% |
Q2 2015 | $8,641,000 | +12.6% | 38,899 | +0.7% | 0.33% | +8.9% |
Q1 2015 | $7,671,000 | +313.8% | 38,623 | +162.7% | 0.30% | +267.5% |
Q2 2014 | $1,854,000 | -73.5% | 14,701 | -72.3% | 0.08% | -83.3% |
Q1 2014 | $6,999,000 | – | 53,092 | – | 0.50% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Brave Warrior Advisors | 5,701,010 | $1,266,479,000 | 36.57% |
Ruane, Cunniff & Goldfarb | 33,884,050 | $7,527,342,000 | 35.90% |
LeVasseur Capital Partners LLC | 188,804 | $41,943,000 | 34.97% |
Pershing Square Capital Management | 19,473,933 | $4,326,134,000 | 29.95% |
FARLEY CAPITAL L.P. | 141,020 | $31,328,000 | 24.16% |
Ratan Capital Management LP | 1,038,033 | $230,599,000 | 21.97% |
Marble Arch Investments | 1,069,000 | $237,478,000 | 20.47% |
Arrow Capital Management, LLC | 144,461 | $32,092,000 | 18.04% |
Tesuji Partners | 1,368,040 | $303,910,000 | 17.93% |
ValueAct Holdings | 14,994,261 | $3,330,975,000 | 17.54% |